PFESeagen, a wholly owned subsidiary of PfizerRunning, no new patients
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Uterine Neoplasms · Uterine Cervical Neoplasms · Biliary Tract Neoplasms · Urologic Neoplasms · Carcinoma, Non-Small-Cell Lung · HER2 Mutations Breast Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 217 (final count)
- Started
- Jan 11, 2021
- Main results expected
- Nov 1, 2023
- Fully finished
- Dec 31, 2026
- Results posted
- Nov 13, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (cORR) as Assessed by Investigator
Measured over: From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 28.3 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04579380 · record last updated 2026-08-21 · checked 2026-11-09 15:47 UTC